Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Erica Jennison, Christopher D. Byrne

Clin Mol Hepatol. 2021;27(1):22-43. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0129

View: 9929 Download: 434 Web of Science: 50 Crossref: 52

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Beatriz Garcia Mendes, Bernd Schnabl

Clin Mol Hepatol. 2020;26(4):595-605. Published online September 11, 2020

DOI: https://doi.org/10.3350/cmh.2020.0086

View: 8389 Download: 239 Web of Science: 21 Crossref: 24

Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao

Received April 28, 2024 Accepted July 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0315 [Accepted]

View: 778 Download: 87

1 |

Viewed By 6001	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5524	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5308	MAFLD: How is it different from NAFLD?
Viewed By 5279	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4860	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 146	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 109	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search